Evidence map›Paper›PMID 16428778›Full record

ArticleInfection and immunity2006

Intranasal exposure to bacterial superantigens induces airway inflammation in HLA class II transgenic mice.

Govindarajan Rajagopalan, Koji Iijima, Manisha Singh, Hirohito Kita, Robin Patel, Chella S David

Registry-linked trialAbstract read
In one paragraph

Article in Infection and immunity, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06719219 (A Phase I, Randomized, Double-Blinded and Controlled Trial to Evaluate Safety and Immunogenicity of an Investigational Multicomponent Staphylococcus Aureus Toxoid Vaccine), which is not on this map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06719219 phase1completednot on this mapstarted 2025, after this paper: background citation

A Phase I, Randomized, Double-Blinded and Controlled Trial to Evaluate Safety and Immunogenicity of an Investigational Multicomponent Staphylococcus Aureus Toxoid Vaccine (LTB-SA7) in Healthy Adults.

TypeinterventionalSponsorLimmaTech Biologics AGRan2025 to 2026Enrolled129ConditionsStaphylococcus (S.) Aureus InfectionArmsLTB-SA7, Placebo
3 · Its place in the literature

Who cites it

30 citing papers in PubMed.

  1. Article
  2. Article
  3. IFN-American journal of respiratory cell and molecular biology · 2023
    Article
  4. The Role ofInternational journal of molecular sciences · 2022
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Therapeutic blockade of CD54 attenuates pulmonary barrier damage in T cell-induced acute lung injury.American journal of physiology. Lung cellular and molecular physiology · 2017
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Govindarajan RajagopalanDepartment of Immunology, Mayo Clinic College of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
Koji Iijima
Manisha Singh
Hirohito Kita
Robin Patel
Chella S David

Funding

GENETICS AND SEROLOGY OF H-2 (IR) LINKED IA ANTIGENSR01AI014764 · NIAID · MAYO CLINIC COLL OF MEDICINE, ROCHESTER · PI DAVID, CHELLA S · 1985 to 2004
$1.7M
STRUCTURE EXPRESSION REGULATION OF MICE/HUMAN IA GENESR37AI014764 · NIAID · MAYO CLINIC COLL OF MEDICINE, ROCHESTER · PI DAVID, CHELLA S · 1990 to 1999
–
NIAID NIH HHS AI14764NIAID NIH HHS R01 AI014764NIAID NIH HHS R37 AI014764
6 · The paper itself

Abstract

Staphylococcus aureus is widely prevalent in the nasopharynges of healthy individuals (carriers) but can also cause serious infections. S. aureus can elaborate a variety of superantigen exotoxins in "carrier" or "pathogenic" states. Streptococcus pyogenes can also colonize the nasopharynx and elaborate superantigens. Unlike the acute effects of superantigen exotoxins absorbed through the gut or vaginal mucosa, little is known regarding the pathogenesis of superantigens entering through the intranasal route. In the current study, we evaluated the local and systemic effects of staphylococcal enterotoxin B (SEB) and streptococcal pyrogenic exotoxin A (SPEA) delivered through the intranasal route. Superantigens were administered intranasally on multiple occasions, and experimental animals were sacrificed on day 8 for experimental analyses. SEB-induced airway inflammation was more pronounced for HLA-DR3 transgenic mice than for BALB/c mice, consistent with bacterial superantigens binding more efficiently to human than murine major histocompatibility complex class II. The nature of the airway inflammation in HLA-DR3 mice was determined by the concentration of SEB applied intranasally. Low concentrations (20 ng) induced eosinophilic airway inflammation as well as eosinophil degranulation, whereas intranasal exposure to higher concentrations (2,000 ng) resulted in neutrophilic airway inflammation, permanent airway destruction, toxic shock, and mortality. SEB-induced eosinophilic inflammatory response was enhanced in signal transducer and activator of transcription (STAT)-4-deficient HLA-DQ8 transgenic mice with defective interleukin-12 signaling. Intranasal administration of SPEA induced airway inflammation and systemic immune activation in HLA-DQ8 transgenic mice. In conclusion, repeated chronic intranasal exposure to bacterial superantigens causes airway inflammation and systemic immune activation.

Indexed as

InflammationLungAdministration, IntranasalAnimalsBacterial ProteinsEnterotoxinsExotoxinsHistocompatibility Antigens Class IIHLA-DR3 AntigenMembrane ProteinsMiceMice, Inbred BALB CMice, Inbred C57BLMice, TransgenicSuperantigensBacterial Proteinsenterotoxin B, staphylococcalEnterotoxinsExotoxinsHistocompatibility Antigens Class IIHLA-DR3 AntigenMembrane ProteinsSpeA protein, Streptococcus pyogenesSuperantigens

Identifiers

PMID16428778
PMCPMC1360368

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.